Across TCGA pan-cancer cohorts, SRPK3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SRPK3 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SRPK3 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated SRPK3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, UCEC, and COAD are the cancer types where SRPK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.411	.031	11	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SRPK3 tumor-vs-normal RNA expression · all SRPK3 data types